ClinicalTrials.gg
Active, not recruitingNCT05983250LEVELUpdated Jul 24, 2026

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

A Phase 3 interventional study of TNX-103 and Placebo in Pulmonary Hypertension, sponsored by Tenax Therapeutics, Inc.. Active, not recruiting at 42 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Tenax Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 397 studies in Hypertension, Pulmonary with a site in United States — 73 open to participants now, 87 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Planned enrollment
46th of 286
230 · median 30
Started
2024
with 13 others
Phase 3
65 of 397
6 open now
Primary completion
2026-06
later than 16 of 85 live
Registered
341st of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 46th largest by planned enrollment of the 286 interventional ones that give a count, is one of 14 that started in 2024, is one of 65 in phase 3, reaches primary completion later than 16 of the 85 other live ones, and was the 341st registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

73 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).

Read the detailed description

This is a Phase 3, double-blind, randomized, placebo-controlled study of oral levosimendan in patients with PH-HFpEF. There will be a Screening Period of up to 30 days. Subjects will provide written informed consent prior to completing any study procedures. Upon meeting all eligibility criteria, patients will continue to the 12-week randomized, double-blind treatment phase. Approximately 230 subjects will be randomized in a 1:1 ratio to receive an oral dose of levosimendan or placebo

All randomized subjects will have the option to enter the 92-week OLE following the completion of all study events at Week 12.

03

Conditions studied

  • Pulmonary Hypertension

Keywords

  • HFpEF
  • Pulmonary hypertension group 2
  • PH-HFpEF
  • Heart Failure
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women, greater than or equal to18 to 85 years of age.
  2. Class II or III or NYHA class IV symptoms.
  3. A diagnosis of World Health Organization (WHO) Group 2 PH-HFpEF with qualifying hemodynamics
  4. Qualifying Baseline RHC.
  5. Qualifying echocardiogram
  6. Qualifying 6-MWD
  7. A 48-hour ambulatory cardiac rhythm monitor during the Screening Period.
  8. Requirements related to child bearing potential, , and egg/sperm donation

Exclusion criteria

Exclusion Criteria:

  1. A diagnosis of PH WHO Groups 1, 3, 4, or 5.
  2. Echocardiographic evidence for hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy
  3. Structural heart repair or replacement of the aortic valve or mitral valve (surgical or percutaneous). OR, planned valve intervention. OR, the presence of significant valve disease
  4. A diagnosis of pre-existing lung disease
  5. History of severe allergic or anaphylactic reaction or to the in the product.
  6. Major surgery within 60 days.
  7. Prior heart, lung, or heart-lung transplants or of \<12 months
  8. History of other diseases that may limit or complicate participation in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
230 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Active comparator
    TNX-103

    oral levosimendan

    Drug: TNX-103

Interventions

  • oral levosimendan 1 mg

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in Six-minute walk distance

    Time frame: 12 weeks

Secondary outcomes

  1. KCCQ

    Change in KCCQ

    Time frame: 12 weeks

  2. Clinical Worsening Events

    Time frame: 12 weeks

  3. Change in NT-proBNP

    Decreases in NT-proBNP may indicate an improvement in symptoms

    Time frame: 12 weeks

  4. Change NYHA functional class

    On a scale of I-IV. Lower scores may indicate improvement in symptoms

    Time frame: 12 weeks

07

Study locations

42 sites
  • Tenax Investigational Site
    Tucson, Arizona 85721, United States
  • Tenax Investigational Site
    La Jolla, California 92037, United States
  • Tenax Investigational Site
    Los Angeles, California 90033, United States
  • Tenax Investigational Site
    Los Angeles, California 90048, United States
  • Tenax Investigational Site
    Sacramento, California 95817, United States
  • Tenax Investigational Site
    San Francisco, California 94143, United States
  • Tenax Investigational Site
    Torrance, California 90502, United States
  • Tenax Investigational Site
    Jacksonville, Florida 32224, United States
  • Tenax Investigational Site
    Winter Haven, Florida 33881, United States
  • Tenax Investigational Site
    Atlanta, Georgia 30322, United States
  • Tenax Investigational Site
    Chicago, Illinois 60208, United States
  • Tenax Investigational Site
    Chicago, Illinois 60637, United States
  • Tenax Investigational Site
    Galesburg, Illinois 61401, United States
  • Tenax Investigational Site
    Indianapolis, Indiana 46202, United States
  • Tenax Investigational Site
    Indianapolis, Indiana 46260, United States
  • Tenax Investigational Site
    Louisville, Kentucky 40202, United States
  • Tenax Investigational Site
    Boston, Massachusetts 02114, United States
  • Tenax Investigational Site
    Minneapolis, Minnesota 55455, United States
  • Tenax Investigational Site
    Rochester, Minnesota 55905, United States
  • Tenax Investigational Site
    St Louis, Missouri 63136, United States
  • Tenax Investigational Site
    Omaha, Nebraska 68198, United States
  • Tenax Investigational Site
    New York, New York 10021, United States
  • Tenax Investigational Site
    New York, New York 10029, United States
  • Tenax Investigational Site
    Rochester, New York 14621, United States
  • Tenax Investigational Site
    Roslyn, New York 11576, United States
  • Tenax Investigational Site
    Durham, North Carolina 27710, United States
  • Tenax Investigational Site
    Greensboro, North Carolina 27401, United States
  • Tenax Investigational Site
    Cincinnati, Ohio 45267, United States
  • Tenax Investigational Site
    Columbus, Ohio 43214, United States
  • Tenax Investigational Site
    Pittsburgh, Pennsylvania 15212, United States
  • Tenax Investigational Site
    Providence, Rhode Island 02903, United States
  • Tenax Investigational Site
    Charleston, South Carolina 29425, United States
  • Tenax Investigational Site
    Columbia, South Carolina 29044, United States
  • Tenax Investigational Site
    Dallas, Texas 75204, United States
  • Tenax Investigational Site
    Dallas, Texas 75390, United States
  • Tenax Investigational Site
    Lubbock, Texas 79430, United States
  • Tenax Investigational Site
    Plano, Texas 75093, United States
  • Tenax Investigational Site
    Murray, Utah 84107, United States
  • Tenax Investigational Site
    Richmond, Virginia 23298, United States
  • Tenax Investigational Site
    Madison, Wisconsin 53792, United States
  • Tenax Investigational Site
    Winnipeg, Manitoba, Canada
  • Tenax Investigational Site
    London, Ontario N6A 5A5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jun 2026, 29 months.

Of 31 phase 3 interventional studies under Hypertension, Pulmonary, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 83. This study's 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2023
First posted
Aug 9, 2023
StartActual
Jan 10, 2024
Primary completionActual
Jun 30, 2026
CompletionEst.
Oct 30, 2028
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05983250
Lead sponsor
Tenax Therapeutics, Inc.
Collaborators
Medpace, Inc., Northwestern University
Responsible party
Sponsor
First posted
Aug 9, 2023
Start date
Jan 10, 2024
Primary completion
Jun 30, 2026
Completion
Oct 30, 2028 (estimated)
Last update
Jul 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TNX-103

Start the discussion